Retatrutide

Specifications Retartrutide:

Company: Hilma Biocare

Retartrutide (LY-3437943) is a drug intended for the treatment of obesity. It is a triple receptor agonist for GLP-1 (Glucagon-like peptide-1), GIP (Gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). Retartrutide is a 39-amino acid peptide that is resistant to cleavage by DPP4, the enzyme that cleaves GLP-1 and GIP. Retartrutide is constructed from a GIP peptide backbone to achieve triple agonist activity against GLP-1R, GIP, and GCGR.

Indication

Treatment of type 2 diabetes mellitus and weight loss. Retartrutide is used to improve glycemic control in combination with diet and exercises.

Mechanism Of Action

Retartrutide exerts its therapeutic effect through several mechanisms.

1. The drug mimics the GLP-1 hormone, which is naturally released after a meal. This hormone sends a satiety signal to the brain, helping to reduce appetite and prevent overeating. Thus, the first mechanism is that Retatrutide promotes a longer feeling of fullness.
2. As a GLP-1 and GCGR agonist, Retatrutide enhances insulin release from the pancreas while simultaneously reducing glucagon release, which leads to an increase in blood sugar levels and stabilization of energy levels. Thus, the second mechanism can be described as stimulating metabolism: using the energy obtained from food for vital processes in the body instead of storing it as fat. This process ultimately leads to weight loss and may help lower blood pressure.
3. Retatrutide prevents sharp drops in blood sugar levels, which often lead to food cravings and/or irregular eating habits, ultimately leading to overeating. This effect may make it easier to adhere to a weight loss plan and monitor a diet plan.

Clinical studies have shown that Retatrutide can lead to weight loss in as little as 4 weeks. Results from clinical trials demonstrate that in adults with obesity or overweight (non-diabetic) who are treated with Retatrutide, body weight loss can reach 15-35% after completion of treatment.